Verona Pharma plc Sponsored ADR Stock

$28.76

4.05% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Verona Pharma plc Sponsored ADR Stock price

$28.76

+24.29 543.40% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+1.12 4.05%

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.24b
Enterprise Value	$2.06b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	13.32
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-131.16m
Free Cash Flow (TTM) Free Cash Flow	$-53.92m
Cash position	$404.60m
EPS (TTM) EPS	$-1.56
P/E forward	negative
P/S forward	323.89
EV/Sales forward	297.00
Short interest	11.38%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

7x Buy

100%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.90 0.90	7% 7% -
Gross Profit	-0.90 -0.90	76% 76% -
- Selling and Administrative Expenses	96 96	178% 178% -
- Research and Development Expense	33 33	24% 24% -
EBITDA	-130 -130	110% 110% -
- Depreciation and Amortization	0.90 0.90	45% 45% -
EBIT (Operating Income) EBIT	-131 -131	110% 110% -
Net Profit	-126 -126	143% 143% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Verona Pharma plc Sponsored ADR Stock News

Positive

Seeking Alpha

●

14 days ago

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.

Neutral

GlobeNewsWire

●

23 days ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.

Neutral

Seeking Alpha

●

about 2 months ago

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selv...

More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	David Zaccardelli
Employees	79
Founded	2005
Website	www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now